Evidence map›Paper›PMID 40225167›Full record

ArticleHuman mutation2023

Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.

Hannie Douben, Marianne Hoogeveen-Westerveld, Mark Nellist, Jesse Louwen, Marian Kroos-de Haan, Mattijs Punt, Babeth van Ommeren, Leontine van Unen, Peter Elfferich, Esmee Kasteleijn and 8 more

Abstract read
In one paragraph

Article in Human mutation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Biomarker Landscape in RASopathies.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hannie DoubenDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Marianne Hoogeveen-WesterveldDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Mark NellistDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.ORCID 0000-0003-0949-1566
Jesse LouwenDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Marian Kroos-de HaanDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Mattijs PuntDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Babeth van OmmerenDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Leontine van UnenDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Peter ElfferichDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Esmee KasteleijnDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Yolande van BeverDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Margreethe van VlietDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Rianne OostenbrinkDepartment of Pediatrics, Erasmus University Medical Center, Rotterdam, Netherlands.
Jasper J SarisDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.ORCID 0000-0001-9232-267X
Anja WagnerDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Yvette van IerlandDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.
Tjakko van HamDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.ORCID 0000-0002-2175-8713
Rick van MinkelenDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, Netherlands.ORCID 0000-0003-2770-2646

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1) and Legius syndrome (LS) are caused by inactivating variants in

Indexed as

Cafe-au-Lait SpotsNeurofibromatosis 1Neurofibromin 1RNA PrecursorsRNA SplicingAdaptor Proteins, Signal TransducingHumansIntracellular Signaling Peptides and ProteinsMembrane ProteinsMutationAdaptor Proteins, Signal TransducingIntracellular Signaling Peptides and ProteinsMembrane ProteinsNeurofibromin 1NF1 protein, humanRNA PrecursorsSPRED1 protein, human

Identifiers

PMID40225167
PMCPMC11918873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.